XML 72 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's receivable from Janssen $ 9,977 $ 8,822  
AbbVie's payable to Janssen $ 22,699 20,159  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Janssen Biotech, Inc | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 304 295 $ 321
AbbVie's receivable from Janssen 294 283  
AbbVie's payable to Janssen 509 562  
Janssen Biotech, Inc | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 2,018 2,012 1,803
Janssen Biotech, Inc | Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 1,087 1,009 844
Genentech, Inc. | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 703 533 320
AbbVie's share of development costs (included in R&D) 140 129 128
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 40 $ 46 $ 41